| Long-term Treatment Outcomes of Intravitreal Bevacizumab Treatment for Myopic Choroidal Neovascularization. |
|
Jeong Min Lee, Jong Woo Kim, Dong Won Lee, Jae Hui Kim |
|
Department of Ophthalmology, Kim's Eye Hospital, Konyang University College of Medicine, Seoul, Korea. kjh7997@daum.net |
| 근시 맥락막신생혈관에 대한 유리체내 베바시주맙 치료의 장기 결과 |
|
이정민·김종우·이동원·김재휘 |
|
건양대학교 의과대학 김안과병원 안과학교실 |
Correspondence:
Jae Hui Kim,
Email: kjh7997@daum.net
|
|
Received: 29 November 2018 • Revised: 3 February 2019 • Accepted: 16 May 2019 |
| Abstract |
PURPOSE
To evaluate the long-term treatment outcomes of bevacizumab therapy in patients with myopic choroidal neovascularization (CNV). METHODS: A retrospective review was performed of medical records regarding 43 eyes with myopic CNV that were treated with intravitreal bevacizumab injection. Visual acuity at diagnosis was compared with that measured at the final follow-up; the incidence and timing of re-activation were evaluated. In addition, factors associated with final follow-up were analyzed. RESULTS: Mean patient age was 39.3 ± 12.9 years and mean spherical equivalent (SE) was −11.9 ± 4.4 diopters. Patients were followed-up at a mean of 42.1 ± 17.0 months. Re-activation of the lesion was noted in 17 eyes (39.5%). The mean time to first re-activation was 19.5 ± 15.4 months from the time that resolution of subretinal fluid/retinal fluid was confirmed after initial treatment. The mean visual acuity (the logarithm of the minimal angle of resolution) was 0.40 ± 0.25 at diagnosis and 0.26 ± 0.31 at the final follow-up. Visual acuity at the final follow-up was significantly improved when compared with the baseline value (p = 0.005). Patient age (p < 0.001), SE (p = 0.003), and visual acuity at diagnosis (p < 0.001) were significantly associated with visual acuity at the final follow-up. CONCLUSIONS: Bevacizumab therapy was a useful method for long-term treatment of myopic CNV. The observation of relatively late re-activation after the initial treatment suggests a need for continuous long-term follow-up. |
| Key Words:
Bevacizumab;Choroidal neovascularization;Myopia |
PDF Links
Full text via DOI
Download Citation
